Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
Abstract: There is disclosed stable pharmaceutical compositions containing pharmaceutically acceptable salts of aminopterin surface deposited onto solid excipients. The stable pharmaceutical compositions are hermetically sealed from the atmosphere. The formation of degradation products of aminopterin is reduced or eliminated.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
October 27, 2015
Assignee:
Aminopterin LLC
Inventors:
Absar Faruqui, John A. Zebala, Barton A. Kamen
Abstract: There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
January 23, 2010
Date of Patent:
January 8, 2013
Assignee:
Aminopterin, LLC
Inventors:
John A. Zebala, Dean Y. Maeda, Joel R. Morgan, Stuart J. Kahn
Abstract: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.